One of the big winners in the health-care space on Friday was Illumina (ILMN 2.83%), up 10% for the day after the company outlined its strategic vision. The big news from the report was its new genome sequencer machine, designed to process a staggering 20,000 genomes a year, at a price point of $1,000. This price has long been a target for the industry, and Illumina's reaching it should lead to widespread use of its machine. Releasing its sequencer now also gets it out ahead of competitor Life Technologies' (NASDAQ: LIFE) $1,000 sequencer, and it positions Illumina to dominate what could be a $20 billion market. In this video, Fool health-care analyst David Williamson tells investors just how big the potential for Illumina in this space could be, and what to watch for from here.
Friday's Biggest Health-Care Winner: Illumina, Inc.
By Dave Williamson – Jan 18, 2014 at 5:24PM
NASDAQ: ILMN
Illumina
Market Cap
$15B
Today's Change
(-2.83%) $2.77
Current Price
$95.03
Price as of October 29, 2025 at 4:00 PM ET
Illumina's new machine could be enormous for genome processing, and for investors.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid